From this work, we propose that CXCL13, circulating B. pertussis+ MBCs, and pertussis specific antibody titers should be evaluated further to determine their potential as biomarkers for pertussis vaccine-induced immunity (Figure 6). This evidence concerns the gene CXCL13 and pertussis.